Get the Stockscreener App
15.31
0.07%
0.010
After Hours:
15.33
0.02
+0.13%
Cvrx Inc stock is traded at $15.31, with a volume of 150.26K.
It is up +0.07% in the last 24 hours and up +52.04% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$15.30
Open:
$15.3
24h Volume:
150.26K
Relative Volume:
0.50
Market Cap:
$366.87M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-7.2905
EPS:
-2.1
Net Cash Flow:
$-40.45M
1W Performance:
+13.24%
1M Performance:
+52.04%
6M Performance:
+105.50%
1Y Performance:
-24.02%
1-Day Range:
$14.90
$15.67
1-Week Range:
$13.38
$16.02
52-Week Range:
$6.40
$33.13
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
15.31 | 366.87M | 47.26M | -58.48M | -40.45M | -2.10 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx Insiders May Regret Not Buying More, Market Cap Hits US$377m - Simply Wall St
Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team - MSN
(CVRX) Trading Report - Stock Traders Daily
Paul Verrastro Sells 1,430 Shares of CVRx, Inc. (NASDAQ:CVRX) Stock - MarketBeat
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock By Investing.com - Investing.com Nigeria
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock - Investing.com
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
CVRx to Present at Piper Sandler 36th Annual Healthcare Conference in December | CVRX Stock News - StockTitan
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
CVRx’s Barostim Gains New CPT Codes - MPO-mag
CVRx Inc (CVRX) Shares Down 6.46% on Nov 13 - GuruFocus.com
(CVRX) Long Term Investment Analysis - Stock Traders Daily
International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx: Impressive Top-Line Growth Seems Priced In - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight Recommendation - MSN
CVRx (NASDAQ:CVRX) Stock Price Expected to Rise, Craig Hallum Analyst Says - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
How the (CVRX) price action is used to our Advantage - Stock Traders Daily
CVRx Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com
Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India
CVRx (NASDAQ:CVRX) Given New $15.00 Price Target at Lake Street Capital - MarketBeat
CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat
CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks
CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada
CVRx: Q3 Earnings Snapshot - The Advocate
CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com
CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2024 Result - GuruFocus.com
CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India
CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Sale |
13.58 |
1,430 |
19,417 |
1,875 |
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):